We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

52 hedge funds and large institutions have $19.7M invested in Insight Molecular Diagnostics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $19.6M → $19.7M (+$140K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.22% less ownership

Funds ownership: 2.56% → 2.35% (-0.22%)

10% less funds holding

Funds holding: 58 → 52 (-6)

74% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 19

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
5
Reduced
19
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DC
Defender Capital
North Carolina
+$33.6K
2
Renaissance Technologies
Renaissance Technologies
New York
+$11.7K
3
TRCT
Tower Research Capital (TRC)
New York
+$7.9K
4
BlackRock
BlackRock
New York
+$2.59K
5
LPL Financial
LPL Financial
California
+$2.43K

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$1.44M
2
AIC
AWM Investment Company
New York
-$179K
3
SSA
Schonfeld Strategic Advisors
New York
-$149K
4
IA
IFP Advisors
Florida
-$98K
5
E
Ergoteles
New York
-$33K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$8.79K -$6.41K -863 -41%
Osaic Holdings
27
Osaic Holdings
Arizona
$8.66K – – –
SSA
28
Schonfeld Strategic Advisors
New York
$7.62K -$149K -20,120 -95%
WW
29
Westshore Wealth
California
$7.09K – – –
UBS Group
30
UBS Group
Switzerland
$6.67K -$6.67K -899 -49%
WJWM
31
Williams Jones Wealth Management
New York
$5.32K – – –
RJFSA
32
Raymond James Financial Services Advisors
Florida
$5.24K -$742 -100 -12%
TSS
33
Two Sigma Securities
New York
$4.42K -$794 -107 -15%
Victory Capital Management
34
Victory Capital Management
Texas
$4.19K -$252 -34 -5%
LCS
35
Levin Capital Strategies
New York
$3.72K – – –
FCH
36
Freestone Capital Holdings
Washington
$3.54K – – –
LP
37
LMR Partners
United Kingdom
$3.54K – – –
PNC Financial Services Group
38
PNC Financial Services Group
Pennsylvania
$3.54K – – –
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$1.48K -$297 -40 -16%
JP Morgan Chase
40
JP Morgan Chase
New York
$1K – – –
RAM
41
Riggs Asset Management
Pennsylvania
$355 – – –
Wells Fargo
42
Wells Fargo
California
$284 -$460 -62 -61%
US Bancorp
43
US Bancorp
Minnesota
$177 – – –
PSB
44
Piscataqua Savings Bank
New Hampshire
$175 – – –
MAM
45
Meeder Asset Management
Ohio
$69 – – –
AFG
46
Albion Financial Group
Utah
$54 – – –
Citigroup
47
Citigroup
New York
$49 -$334 -45 -87%
LC
48
Lindbrook Capital
California
$30 – – –
Group One Trading
49
Group One Trading
Illinois
$9 – – –
AWM
50
Avior Wealth Management
Nebraska
$5 +$7 +1 New
1
2
3

IMDX Hedge Fund Activity: Q1 2023 in Review

52 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2023, worth a combined $19.7M — up 0.72% from $19.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IMDX and 1 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 5 added.

The largest buyer was Defender Capital, adding an estimated $33.6K. The largest seller was Pura Vida Investments, cutting an estimated $1.44M.

  • 52 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2023, down from 58 in Q4 2022.
  • Funds reported $19.7M of Insight Molecular Diagnostics stock for Q1 2023, up 0.72% quarter-over-quarter.
  • 1 fund opened new Insight Molecular Diagnostics positions in Q1 2023 and 7 closed out, a net change of -6 holders.
  • The largest Insight Molecular Diagnostics buyer in Q1 2023 was Defender Capital, an estimated $33.6K added.
  • The largest Insight Molecular Diagnostics seller in Q1 2023 was Pura Vida Investments, an estimated $1.44M sold.

Based on aggregated 13F filings for Q1 2023.